Impact of Palifermin on Transplant Outcomes in Children and Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation

Background: Oral mucositis (OM) is considered to be one of the worst and most debilitating complications of conditioning for hematopoietic cell transplantation (HCT). Prevention and treatment of this complication is one of the utmost priorities of supportive therapy during transplant procedure. The...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-11, Vol.40 (11), p.6531-6537
Main Authors: CZYŻEWSKI, KRZYSZTOF, DĘBSKI, ROBERT, BARTOSZEWICZ, NATALIA, DEMIDOWICZ, EWA, RICHERT-PRZYGOŃSKA, MONIKA, ŁĘCKA, MONIKA, TARASENKO, SONIA, STYCZYŃSKI, JAN
Format: Article
Language:English
Subjects:
Adolescents
Children
Complications
Graft-versus-host reaction
Growth factors
Keratinocyte growth factor
Mucositis
Risk analysis
Risk factors
Stem cell transplantation
Survival
Transplantation
Transplants & implants
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Oral mucositis (OM) is considered to be one of the worst and most debilitating complications of conditioning for hematopoietic cell transplantation (HCT). Prevention and treatment of this complication is one of the utmost priorities of supportive therapy during transplant procedure. The objective of this study was the analysis of the influence of palifermin, keratinocyte growth factor (KGF), on transplant outcomes in patients undergoing allo-HCT. Patients and Methods: A total of 253 allo-HCTs performed between 2003-2018 in patients aged 0-19 years at a single center were analyzed. KGF was administered in 161 HCTs. Uni- and multivariate risk factor analyses were performed. Results: In spite of reducing the duration and grade of mucositis, no prognostic impact of KGF was shown for overall survival, event-free survival, relapse incidence, acute and chronic graft-versus-host disease (GVHD), nor GVHD-free relapse-free survival. Conclusion: Palifermin had no impact on transplant outcomes in children and adolescents undergoing allo-HCT.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14677